- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03581942
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
Phase IB/II Study Combining the PI3K Inhibitor Copanlisib With the BTK Inhibitor Ibrutinib in Patients With Recurrent/Refractory Primary CNS Lymphoma
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Christian Grommes, MD
- Phone Number: 212-610-0344
- Email: grommesc@mskcc.org
Study Contact Backup
- Name: Ingo Mellinghoff, MD
- Phone Number: 646-888-2766
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
-
Middletown, New Jersey, United States, 07748
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
-
Montvale, New Jersey, United States, 07645
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan Kettering Commack (Limited Protocol Activities)
-
Harrison, New York, United States, 10604
- Memorial Sloan Kettering Westchester (Limited Protocol Activities)
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, United States, 11553
- Memorial Sloan Kettering Nassau (Limited protocol activities)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients eligible for inclusion in this study must meet ALL the following criteria:
- Men and woman who are at least 18 years of age on the day of consenting to the study.
- Histologically documented PCNSL
- Relapsed/refractory PCNSL or newly diagnosed PCNSL patients who are deemed medically ineligible by the treating investigator (phase II only) to receive standard first-line chemotherapy. All recurrent/refractory patients need to have received at least one prior CNS directed therapy. There is no restriction on the number of recurrences.
- For recurrent/refractory patients, parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 21 days of study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days of study registration (at the discretion of the investigator).
- ECOG performance status ≤ 2.
- Life expectancy of > 3 months (in the opinion of the investigator).
Adequate bone marrow and organ function shown by:
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
- Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 14 days prior to study registration
- Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 14 days prior to study registration
- International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal
- Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome
- Serum creatinine ≤ 2 times the upper limit of normal
- Creatinine clearance ≥ 30 mL/min
- Lipase ≤ 1.5 x upper limit of normal
Women of childbearing potential (WOCBP) and men must agree to use effective contraception when sexually active. This applies for the time period between signing of the informed consent form and 30 days (for WOCBP) and 90 days (for men) after the last administration of study treatment. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include but are not limited to hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for continuous 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy.
- The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1%), e.g. intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence
- The use of condoms by male patients is required unless the female partner is permanently sterile. Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry
- Must be able to tolerate MRI/CT scans
- Must be able to tolerate lumbar puncture and/or Ommaya taps
- Must have recovered to grade 1 toxicity from prior therapy
- Able to submit up to 20 unstained formalin-fixed, paraffin-embedded (FFPE) slides from the initial or most recent tissue diagnosis for correlative studies
NOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT prevent patients from enrollment into the trial.
Exclusion Criteria:
Patients eligible for this study must NOT MEET ANY of the following criteria:
- Active concurrent malignancy requiring active therapy
- Newly diagnosed PCNSL who qualify for standard methotrexate-based chemotherapy
Excluded medical conditions:
- Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure (New York Heart Association > Class 2), unstable angina, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
- Uncontrolled hypertension despite optimal medical management (per investigator"s assessment)
- Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin >8% or poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of >8%
- Patient is known to have an uncontrolled active systemic infection (>CTCAE grade 2) and recent infection requiring intravenous anti-infective treatment that was completed ≤14 days before the first dose of study drug
- Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism within 3 months before the start of study treatment
- Non-healing wound, ulcer or bone fracture
- Not recovered to a grade 1 from the toxic effects of prior therapy if clinically relevant in the opinion of the investigator (e.g. alopecia)
- Known bleeding diathesis (eg, von Willebrand"s disease) or hemophilia
- Known history of infection with human immunodeficiency virus (HIV) or history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests, or any uncontrolled active systemic infection
- Patient underwent major systemic surgery ≤ 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug
- Unable to swallow capsules or disease significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction
- Any life-threatening illness, medical condition including uncontrolled diabetes mellitus (DM), uncontrolled hypertension or organ system dysfunction that, in the opinion of the investigator, could compromise the subject"s safety or put the study outcomes at undue risk
- Lactating or pregnant
Excluded previous Therapies and medications:
- Any chemotherapy, external beam radiation therapy, or anticancer antibodies within 21 days of the first dose of study drug
- Prior treatment with a PI3K inhibitor, AKT inhibitor, or mTOR inhibitor (prior ibrutinib exposure is allowed)
- Any targeted anticancer therapy ≤ 4 weeks or 5 half-lives, whichever is shorter
- Use of radio- or toxin-immunoconjugates within 70 days of the first dose of study drug
- Concurrent use of warfarin or other vitamin K antagonists (need to be stopped 7 days prior to starting on trial drug)
- Concurrent use of a strong cytochrome P450 (CYP) 3A4/5 inhibitor and inducers (see Appendix 1) (need to be stopped 2 weeks prior to starting on trial drug)
- Enzyme-inducing antiepileptic drugs (EIAED) need to be discontinued and switched to a nonnon-EIAED 2 weeks prior to starting on trial drug)
- Patient requires more than 4 mg of dexamethasone daily or the equivalent
- Patient is using systemic immunosuppressant therapy, including cyclosporine A, tacrolimus, sirolimus, and other such medications, or chronic administration of > 5 mg/day or prednisone or the equivalent. Participants must be off of immunosuppressant therapy for at least 28 days prior to the first dose of the study drug
- Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of > 5 mg/day of prednisone) within 28 days of the first dose of study drug
- Prior allogeneic stem cell transplant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Copanlisib in combination with Ibrutinib
Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off).
Phase II: (Simon two-stage design: 14 patients will be treated at the MTD (including 6 patients from the phaseIb portion) If at least 11 patients respond then an additional 19 patients will be accrued to the second stage.
Patients in the phase II portion of the trial will receive sequential drug dosing.
Patient will be treated in 28-day cycles.
During one cycle, only one drug will be administered with a ibrutinib/copanlisib ratio of 1:2.
Patients will receive Ibrutinib at 840 mg daily during cycle 1 (day 1 through day 28) (28-day cycles), then copanlisib 60mg weekly on day 1, 8, and 15 during cycle 2 and 3. Patients will then repeat the sequence.
|
(MTD) Dose Escalation level 2: Ibrutinib 840 mg daily
(MTD) Copanlisib 60 mg weekly (3w on/1w off)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximum tolerated dose (MTD) (phase Ib)
Time Frame: 1 year
|
The "3+3" design will be applied in the phase Ib portion of the trial.
|
1 year
|
overall response rate (ORR) (phase II)
Time Frame: 1 year
|
To explore the therapeutic efficacy measured by overall response rate (ORR) of Copanlisib in combination with Ibrutinib in patients with refractory/relapsed PCNSL or newly diagnosed PCNSL not able to tolerate standard chemotherapy (phase II)This study will use the modified International Primary CNS Lymphoma Collaborative Group (IPCG)12.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events in terms of incidence and severity (phase Ib and II)
Time Frame: 2 years
|
adverse events at each visit with the NCI CTCAE v4.03 used as a guide for the grading of severity.
|
2 years
|
progression free survival (PFS) (phase II)
Time Frame: 2 years
|
Progression-free survival (PFS) is defined as the time from the date of treatment start to the date of the first documented PD or death due to any cause.
|
2 years
|
duration of response (DOR) (phase II)
Time Frame: 2 years
|
Duration of response is defined as the time from the date of first occurrence of CR or PR to the date of the first documented PD or death due to any cause.
|
2 years
|
overall survival (OS) (phase II)
Time Frame: 2 years
|
Overall survival time (OS) is defined as the time from treatment start to the date of death due to any cause.
|
2 years
|
To evaluate cerebral spinal fluid (CSF) pharmacokinetics of Copanlisib and Ibrutinib and correlate with plasma pharmacokinetics (phase Ib)
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Christian Grommes, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-246
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)United States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.; Janssen Biotech, Inc.RecruitingAdult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)United States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingRefractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System NeoplasmUnited States
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Chang... and other collaboratorsNot yet recruitingPrimary Central Nervous System Lymphoma (PCNSL)
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)France
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Zhengzhou UniversityRecruitingPCNSL | Survival AnalysisChina
-
Huiqiang HuangGuangdong 999 Brain HospitalNot yet recruitingNon Hodgkin Lymphoma | PCNSL | Refractory and Relapsed Primary CNS LymphomaChina
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Nervous System Lymphoma | Recurrent Primary Vitreoretinal DLBCL | Refractory Nervous System Lymphoma | Refractory Primary Vitreoretinal DLBCLUnited States
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Nanchang University; RenJi Hospital; Ningbo... and other collaboratorsRecruitingRecurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)China
Clinical Trials on Ibrutinib
-
Christian BuskeAmgen; Janssen, LPRecruitingWaldenstrom MacroglobulinemiaAustria, Germany, Greece
-
TG Therapeutics, Inc.CompletedMantle Cell Lymphoma | Chronic Lymphocytic LeukemiaUnited States
-
Janssen Research & Development, LLCCompleted
-
Oncternal Therapeutics, IncUniversity of California, San Diego; Pharmacyclics LLC.; California Institute...Active, not recruitingMantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Johnson & Johnson Private LimitedCompletedLymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-CellIndia
-
Janssen Research & Development, LLCCompleted
-
The Lymphoma Academic Research OrganisationJanssen Pharmaceutica N.V., BelgiumTerminatedB-cell LymphomaFrance, Belgium
-
Janssen-Cilag S.p.A.CompletedLeukemia, Lymphocytic, Chronic, B-CellItaly
-
The First Affiliated Hospital with Nanjing Medical...Xian-Janssen Pharmaceutical Ltd.UnknownChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaChina
-
Pharmacyclics Switzerland GmbHJanssen Biotech, Inc., including Johnson & JohnsonEnrolling by invitationLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host DiseaseUnited States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden